Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHCR7 | Q9UBM7 | 3/20 | 0.78 |
| ▸ | ABCB1 | P08183 | 7/20 | 0.60 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.60 |
| ▸ | DRD3 | P35462 | 4/20 | 0.56 |
| ▸ | DRD2 | P14416 | 2/20 | 0.56 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.56 |
| ▸ | DRD4 | P21917 | 2/20 | 0.55 |
| ▸ | DRD1 | P21728 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14739911 | 0.88 | DHCR7 (1.00) | DHCR7ABCB1DRD3DRD2TMEM97 | |
| SCHEMBL14740411 | 0.88 | DHCR7 (0.79) | DHCR7ABCB1ABCG2DRD3DRD2 | |
| SCHEMBL3504140 | 0.88 | DHCR7 (0.79) | DHCR7ABCB1ABCG2DRD3DRD2 | |
| SCHEMBL14740106 | 0.84 | DHCR7 (1.00) | DHCR7ABCB1ABCG2CA2CA9 | |
| SCHEMBL14740471 | 0.83 | DHCR7 (0.73) | DHCR7ABCB1ABCG2CA2CA9 | |
| SCHEMBL3042454 | 0.82 | DHCR7 (0.81) | DHCR7ABCB1ABCG2DRD3DRD4 | |
| SCHEMBL17664977 | 0.81 | DHCR7 (0.79) | DHCR7ABCB1ABCG2CA2CA9 | |
| SCHEMBL14739580 | 0.81 | DHCR7 (1.00) | DHCR7ABCB1ABCG2DRD3DRD2 | |
| SCHEMBL14330769 | 0.81 | DHCR7 (0.79) | DHCR7ABCB1ABCG2CA2CA9 | |
| SCHEMBL13896162 | 0.79 | ABCB1 (0.73) | DHCR7ABCB1ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3589626-B1 | 8-PHENYL-ISOQUINOLINES AND PHARMACEUTICAL COMPOSITION THEREOF USED IN THE TREATMENT OF IRRITABLE BOWEL SYNDROME | UNIV NAT TAIWAN (TW) | 2024-06-12 | — | — | EP | disclosed |
| US-20200071274-A1 | 8-PHENYL-ISOQUINOLINES AND PHARMACEUTICAL COMPOSITION THEREOF USED IN THE TREATMENT OF IRRITABLE BOWEL SYNDROME | NATIONAL TAIWAN UNIVERSITY (TW) | 2020-03-05 | — | — | US | disclosed |
| US-8552028-B2 | 8-phenylisoquinolines and pharmaceutical composition used in treatment for sepsis | NATIONAL TAIWAN UNIVERSITY (TW) | 2013-10-08 | — | — | US | disclosed |
| US-20130059882-A1 | 8-Phenylisoquinolines And Pharmaceutical Composition Used In Treatment For Sepsis | NATIONAL TAIWAN UNIVERSITY (TW) | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059882-A1 | 8-Phenylisoquinolines And Pharmaceutical Composition Used In Treatment For Sepsis | CXCL8, THPO, IL18 | DHCR7 760/4885ABCB1 275/4885ABCG2 1385/4885 |
| US-20200071274-A1 | 8-PHENYL-ISOQUINOLINES AND PHARMACEUTICAL COMPOSITION THEREOF USED IN THE TREATMENT OF IRRITABLE BOWEL SYNDROME | HTR7, GPR27, HTR5A | DHCR7 1398/4885ABCB1 328/4885ABCG2 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.